{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T18:40:00Z","timestamp":1763059200224,"version":"3.30.1"},"reference-count":15,"publisher":"National Center for Global Health and Medicine (JST)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM Open"],"published-print":{"date-parts":[[2024,11,28]]},"DOI":"10.35772\/ghmo.2023.01026","type":"journal-article","created":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T22:12:58Z","timestamp":1724019178000},"page":"95-98","source":"Crossref","is-referenced-by-count":1,"title":["Pain relief effect of metoclopramide vs. sumatriptan for acute migraine attack: A single-center, open-label, cluster-randomized controlled non-inferiority trial"],"prefix":"10.35772","volume":"4","author":[{"given":"Yumi","family":"Funato","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine and Critical Care, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and Critical Care, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and Critical Care, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and Critical Care, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and Critical Care, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and Critical Care, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21485","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020; 21:137.","DOI":"10.1186\/s10194-020-01208-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, Mori M, Kawashima M, Kowa H, Adachi Y, Urakami K, Nakashima K. Population-based door-to-door survey of migraine in Japan: The Daisen study. Headache. 2004; 44:8-19.","DOI":"10.1111\/j.1526-4610.2004.04004.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kelley NE, Tepper DE. Rescue therapy for acute migraine, Part 1: Triptans, dihydroergotamine, and magnesium. Headache. 2012; 52:114-128.","DOI":"10.1111\/j.1526-4610.2011.02062.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: Neuroleptics, antihistamines, and others. Headache. 2012; 52:292-306.","DOI":"10.1111\/j.1526-4610.2011.02070.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Araki N, Takeshima T, Ando N, <i>et al<\/i>. Clinical practice guideline for chronic headache 2013. Neurology and Clinical Neuroscience. 2019; 7: 231-259.","DOI":"10.1111\/ncn3.12322"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Schwarzberg MN. Application of metoclopramide specificity in migraine attacks therapy. Headache. 1994; 34 :439-441.","DOI":"10.1111\/j.1526-4610.1994.hed3407439.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Papers parenteral metoclopramide for acute migraine: Meta-analysis of randomized controlled trials. BMJ. 2004; 329:1369-1373.","DOI":"10.1136\/bmj.38281.595718.7C"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Friedman BW, Corbo J, Lipton RB, Bijur PE, Esses D, Solorzano C, Gallagher EJ. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005; 64:463-468.","DOI":"10.1212\/01.WNL.0000150904.28131.DD"},{"key":"9","unstructured":"9. Talabi S, Masoumi B, Azizkhani R, Esmailian M. Metoclopramide versus sumatriptan for treatment of migraine headache: A randomized clinical trial. J Res Med Sci. 2013; 18: 695-698."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38:1-211.","DOI":"10.1177\/0333102417738202"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Funato Y, Kimura A, Matsuda W, Uemura T, Fukano K, Kobayashi K, Sasaki R. Metoclopramide versus sumatriptan in the treatment of migraine in the emergency department: A single-center, open-label, cluster-randomized controlled non-inferiority trial. Glob Health Med. 2020; 2:259-262.","DOI":"10.35772\/ghm.2020.01011"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Bijur PE, Latimer CT, Gallagher EJ. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. Acad Emerg Med. 2003; 10:390-392.","DOI":"10.1111\/j.1553-2712.2003.tb01355.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Friedman BW, Mulvey L, Esses D, Solorzano C, Paternoster J, Lipton RB, Gallagher EJ. Metoclopramide for acute migraine: A dose-finding randomized clinical trial. Ann Emerg Med. 2011; 57:457-482.e1.","DOI":"10.1016\/j.annemergmed.2010.11.023"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cady RK, Munjal S, Cady RJ, Manley HR, Brand-Schieber E. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. J Headache Pain. 2017; 18:17.","DOI":"10.1186\/s10194-016-0717-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mathew NT, Dexter J, Couch J, <i>et al<\/i>. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992; 49:1271-1276.","DOI":"10.1001\/archneur.1992.00530360073020"}],"container-title":["GHM Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghmo\/4\/2\/4_2023.01026\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T05:14:30Z","timestamp":1733548470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghmo\/4\/2\/4_2023.01026\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.35772\/ghmo.2023.01026","relation":{},"ISSN":["2436-293X","2436-2956"],"issn-type":[{"type":"print","value":"2436-293X"},{"type":"electronic","value":"2436-2956"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"article-number":"2023.01026"}}